AIM ImmunoTech Declares Stock Dividend to Boost Investor Confidence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 31 Dec 25
Source: SeekingAlpha
AIM ImmunoTech Inc. shares surged by 18.25% in pre-market trading as the stock crossed above the 5-day SMA.
This increase is attributed to AIM ImmunoTech's announcement of a 1-for-1000 stock dividend for shareholders, scheduled for distribution on January 13, 2026. The dividend aims to enhance shareholder returns and boost market confidence, with a record date set for January 9, 2026. The company will also compensate fractional shares in cash, further strengthening its relationship with investors.
The stock's positive movement reflects a strategic effort to improve investor trust and engagement, which could lead to increased demand for shares as the dividend date approaches.
Analyst Views on AIM
Wall Street analysts forecast AIM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIM is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.220
Low
22.00
Averages
22.00
High
22.00
Current: 1.220
Low
22.00
Averages
22.00
High
22.00
No data
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
